Carlsmed’s $30 Million Series B Financing Round

MoFo advised Carlsmed on the deal.

Carlsmed announced the completion of its $30 million Series B financing round. Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The company’s aprevo® devices are personalized to improve the standard of care for the surgical treatment of adults with spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create aprevo® spine fusion devices to align with the surgeon’s goals for each patient. The company is planning to use the financing to scale the commercialization of aprevo®, Carlsmed’s FDA cleared personalized surgical devices.

The funding round was led by B Capital Group with additional participation from existing investors, including U.S. Venture Partners, The Vertical Group, Cove Fund and Wavemaker Three-Sixty Health.

The MoFo team included San Diego corporate attorneys Jim Krenn (Picture), Brennan Brodersen, Carey Hughes, and Brooke Maker.

Involved fees earner: Brennen Brodersen – Morrison & Foerster; Carey Hughes – Morrison & Foerster; Jim Krenn – Morrison & Foerster; Brooke Reczka Maker – Morrison & Foerster;

Law Firms: Morrison & Foerster;

Clients: Carlsmed, Inc.;

Martina Bellini

Author: Martina Bellini